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ABSTRACT 
 
Incidence of Hypertension and Type 2 Diabetes among Obstructive Sleep Apnea Patients 
 
By 
 
Dedria Nicole McArthur 
 
May 3, 2016 
 
 
  
Background: Obstructive Sleep Apnea (OSA) is a chronic breathing disorder that is estimated to affect 
20% of the US adult population. Intermittent hypoxia and sleep fragmentation caused by OSA likely 
affects cardiometabolic function. Individuals with OSA might be at risk of developing hypertension and 
type 2 diabetes (T2DM), with a dose-response relationship related to OSA severity. The objective of this 
study was to estimate the association between severity of OSA at diagnosis with 1) incidence of 
hypertension incidence of hypertension and 2) incidence of T2DM. 
 
Methods: We conducted a retrospective cohort study of Kaiser Permanente members diagnosed with 
OSA during 2000-2005. Adults without baseline hypertension or T2DM were eligible. Patients were 
excluded if hypertension or T2DM was diagnosed within one year prior to OSA diagnosis, and right 
censored at the end of follow-up or at the time Kaiser Permanente membership ended. Kaplan-Meier 
curves and Cox Proportional Hazard models were used to estimate the association between OSA 
severity and incident hypertension and incident diabetes.  
Results:  Overall 719 patients were diagnosed with OSA during the study periods; 614 were included as 
those at risk of developing either hypertension (N=265) or T2DM (N=489). Overall, 261 had severe OSA 
at diagnosis. Those with severe OSA were more likely to be middle aged, overweight, and have prevalent 
hypertension or T2DM. Among those without prevalent hypertension at OSA diagnosis, 47.4% (126/266) 
were subsequently diagnosed with hypertension.  Among those without prevalent T2DM at OSA 
diagnosis, 16.3% (80/491) were subsequently diagnosed with T2DM. After adjusting for BMI and 
prevalent T2DM, the hazard rate of incident hypertension among patients with severe OSA was 1.35 
(95%CI: 0.88-2.06) compared to the rate among patients with mild OSA. The hazard rate of incident 
T2DM among patients with severe OSA was 1.49 (95%CI: 0.83-2.67) compared to the rate among 
patients with mild OSA after adjusting for BMI and prevalent hypertension.        
2 
 
 
Discussion:  We found high incidence rates of hypertension and T2DM among adults diagnosed with 
OSA.  Severe OSA at diagnosis was associated with increased risk of either incident hypertension or 
T2DM, but not significantly (for p≤0.05).  
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Chapter 1: Introduction 
1.1 Background 
 Obstructive sleep apnea (OSA) is a chronic condition that is characterized by frequent 
episodes of upper airway collapse while sleeping.
1
 It’s estimated that about 25% of the US 
population is at high risk of developing OSA, and according a prospective, observational study 
performed by Finkel, et al., the estimated prevalence was 20% in adult population (18≥).2 These 
numbers are expected to rise in the coming years mainly due to the obesity epidemic plaguing 
the US. Even with a high prevalence, it is estimated that up to 90% of OSA patients go 
undiagnosed, due to low awareness about OSA, lack of routine screening, and limited numbers 
of sleep study facilities.
2
  
 The primary diagnostic method of OSA is polysomnogram (PSG). A PSG is conducted at 
a sleep lab or sleep center and requires 24 hours of observation.
3
 During the sleep study several 
variables are measured, which include eye movement, brain activity, blood pressure, and heart 
rate. The PSG study also measures the number of apneas and hypopneas, as well as oxygen 
levels in the body. An apnea occurs when the complete cessation of airflow occurs for at least 10 
seconds; whereas hypopnea is when there is a reduction of airflow but also includes either 
desaturation of oxygen of 3% to 4% or an arousal from sleep occurs. The apnea-hypopnea index 
or AHI is used to calculate if an individual has sleep apnea and the severity.
3
  
 Over time, persistent intermittent hypoxia and sleep fragmentation caused by OSA can 
affect the function of the brain and cardiovascular system as well as alter the body’s metabolic 
balance. Three studies conducted between the 1990s to early 2000s found that patients with OSA 
were at a higher risk for developing many other chronic diseases such as congestive heart failure 
12 
 
(2.38 odds ratio compared to 1.13)
4
, hypertension (6.85 odds ratio for moderate-severe OSA 
compared to 0.89 for snoring) 
5
, 
 
and type 2 diabetes (T2DM) (1.49,1.93,and 3.69 odds ratio for 
mild, moderate, and severe OSA respectively).
6
 Patients with undiagnosed and untreated OSA 
not only increase their risk of other diseases, but they also increased healthcare utilization and 
costs.
7
 A case-control study performed in Manitoba, Canada looked at healthcare costs and 
utilization records over a five year period from the OSA diagnoses date for 773 OSA adults. The 
study found that OSA patients spent on average $1,912 compared to the control group who spent 
$1,495 on healthcare related items such as office visits and medications. They also found that 
individuals who suffered from OSA had on average 36.7 physician visits versus the control 
group that had 29.9 visits.
8
  
 There is currently little information on the incidence of hypertension and T2DM among 
patients with OSA. The lack of information may partly be due to the difficulty in diagnosing 
individuals with OSA. In many cases the patient has been suffering from OSA for years before 
being correctly diagnosed. Some studies have reported that certain demographic factors such as 
BMI, gender, age, and OSA severity play a role in increasing one’s risk of developing either 
hypertension or type 2 diabetes in people with OSA. Better understanding the relationship 
between hypertension and OSA as well as T2DM and OSA could assist with better diagnosis and 
management of OSA and other chronic diseases.  
1.2 Purpose of Study 
The primary purpose of this study is to estimate the association between OSA severity and 
incident hypertension and type 2 diabetes (T2DM).  A secondary purpose is to examine whether 
13 
 
factors such as gender, age, BMI, or baseline co-morbidity are associated with incidence of 
T2DM or hypertension in patients with OSA. 
 
Chapter 2: Literature Review 
2.1 Obstructive Sleep Apnea 
Obstructive sleep apnea (OSA) is characterized by repetitive airway obstruction due to 
the throat muscles intermittently relaxing during sleep.
3,6,9 
 Individuals with OSA may experience 
excessive daytime sleepiness, snoring, observed episodes of breathing cessation during sleep, 
abrupt awakening with shortness of breath, awakening with dry mouth, sore throat, or chest pain, 
morning headaches, difficulty concentrating during the day, mood changes, and insomnia.
3,6,9
 
The primary method for diagnosis of OSA is laboratory full night polysomnography 
(PSG).
3,9
 PSG involves overnight monitoring of several physiological variables such as 
electroencephalography, eye movement, muscle tone, respiratory efforts, airflow, and oxygen 
saturation. During the monitoring, the number of apneas and hypopneas are counted. An apnea 
occurs when the complete cessation of airflow occurs for at least 10 seconds, and hypopnea is 
when there is a reduction of airflow but also includes either desaturation of oxygen of at 3% to 
4% or an arousal from sleep occurs. The apnea-hypopnea index (AHI) is the total number of 
apneas and hypopneas per hour, and this is used as the basis for OSA diagnosis. The level of 
severity of OSA is graded using the commonly accepted clinical criteria: no OSA (AHI < 5), 
mild OSA (AHI ≥5 but less than 15), moderate OSA (AHI ≥15 but less than 30), and severe 
OSA (AHI≥30).9 
14 
 
Treatment for OSA can differ depending on the severity. Lifestyle changes are the main 
recommendation for individuals with mild OSA.
10
 These changes could include losing weight, 
regular exercise, not drinking several hours before bed, smoking cessation, or choosing a 
sleeping position that is not on the back.
 If sleep doesn’t improve or the individual has moderate 
to severe OSA other treatments such as devices or surgeries maybe recommended.
10 
The most 
common treatment for OSA is continuous positive airway pressure (CPAP). This therapy 
consists of a small machine that supplies a constant stream of steady air pressure through the 
nasal passageway.
9,10  
The constant stream of air will keep the upper airway open which prevents 
OSA and snoring.
10
 However many OSA patients find the CPAP machine uncomfortable, so 
adherence to it is small. In cases where the patient has trouble with the CPAP, the doctor may 
recommend the bilevel positive airway pressure (BPAP) machine. The BPAP delivers a preset 
amount of pressure when an individual breathes in and a different amount when the individual 
breathes out.
10 
When the aforementioned devices and lifestyle changes are ineffective in preventing 
OSA, the next step is surgery. Tissue can be surgically removed from the back of the mouth and 
top of the throat. Tonsils and adenoids are commonly removed during this surgery as well.
10
 
Another option is maxillomandibular or jaw surgery. In this procedure, the upper and lower parts 
of the jaw are moved forward away from the rest of the facial bones. The space between the 
tongue and soft palate is enlarged, and the chances of airway obstruction are less likely. When all 
other treatments and surgeries have failed or an individual has life threatening OSA the doctor 
may recommend a tracheostomy. The surgeon would create an opening in the neck and insert a 
metal or plastic tube for breathing. This would bypass the throat preventing obstruction.
10
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Studies have found several risk factors that increase an individual’s chances of 
developing OSA. The strongest risk factor is obesity. BMI, neck circumference, and waist-to-hip 
ratio have all shown a relationship between weight gain and OSA.
11,12,13
 Several studies have 
reported a relationship between obesity and OSA. A 2003 cross-sectional study of 690 adults 
taken from the Wisconsin Sleep Study by Young and colleagues reported that for adults, 60 years 
and younger, every point increase in BMI increased the odds of developing OSA is 1.14 (CI: 
1.10-1.19).
12
   Other risk factors included being middle aged (up to 65)
14
, male gender
15
, post-
menopause
16
, craniofacial abnormalities
17
, upper airway anatomy abnormalities
18
, smoking
13
, 
alcohol consumption before bed
19
, and genetic predisposition
13
.
 
 
Three population-based longitudinal studies assisted with estimating the incidence of 
OSA (Table 1). In the Cleveland Family Study, the researchers found that the majority of the 286 
subjects did not develop OSA after five years; however, 16% developed mild OSA, and 7.5% 
had moderate to severe OSA.
6
 Other studies have encountered similar results. The five-year 
follow-up of the Sleep Heart Health Study found that of the 2,968 participants 11.1% of men and 
4.9% of women developed moderate to severe OSA.
11
The Wisconsin Sleep Cohort Study had a 
total of 690 subjects and after a four-year follow-up about 10.6% of subjects developed OSA.
7 
One of the largest population-based sleep studies, Wisconsin Sleep Cohort Study, 
estimated the prevalence of OSA as 2% in women and 4% of men in the general population. 
Other studies have yielded similar results. However, certain disorders have a higher prevalence 
such as heart disease, resistant and systemic hypertension, T2DM, and polycystic ovary 
syndrome to name a few.
7  
The increased prevalence of other disorders in OSA patients 
originated from the intermittent hypoxia and sleep fragmentation that OSA causes.
20
 A 
consequence of intermittent hypoxia and sleep fragmentation is increased levels of oxidative 
16 
 
stress, low-grade inflammation, activation of the sympathetic nervous system, and deregulation 
of the hypothalamic-pituitary-adrenal axis.
20
  
2.2 Obstructive Sleep Apnea and Type 2 Diabetes 
 Studies over the years have been building evidence suggesting a relationship between 
OSA and diabetes. OSA and diabetes have similar risk factors such as obesity. However, once 
these factors have been accounted for, an independent relationship is still demonstrated.
1
 The 
prevalence of T2DM  in OSA patients is estimated in the range of 15-30 %, but depending on 
how the researchers define OSA or the study population the prevalence could be as high as 
40%.
1 
According to the American Diabetes Association, the prevalence of diabetes in the general 
US population is 9.3%.
21 
 A cross-sectional study conducted by Priou,  et al aimed at determining the association 
between OSA severity and glycated hemoglobin (HbA1c), included 1,599 adults (475 females 
and 1,124 males) from western France from 05/15/2007 thru 11/30/2011.
29
 A dose-response was 
found between individuals with a HbA1c greater than 6% and OSA severity. There were 10.8% 
of patients with HbA1c  ≥ 6% who had an AHI less than 5 whereas patients with an AHI over 50 
were 34.2%.
29
   
Diabetes mellitus is a complex chronic metabolic disease characterized by high fasting 
blood glucose.
22
 This disease occurs when the pancreas cannot produce enough insulin, or the 
body cannot properly use the insulin produced.
23
 Glucose is the basic unit of complex 
carbohydrates which is then broken down to be used for energy in the body. Excess glucose is 
stored as glycogen, in limited quantities, in fat cells around the body.
22
 The symptoms of 
diabetes are excessive excretion of urine, thirst, constant hunger, weight loss, vision changes, and 
17 
 
fatigue.
23
 Type 2 diabetes (T2DM) is developed when the body can no longer effectively use the 
insulin it produces, because of insulin resistance.
22-23
 T2DM is mainly a result of excess body 
weight and physical inactivity and comprises 90% of diabetic cases worldwide.
23
   
 Complications from diabetes are developed gradually over time and are seen more 
frequently in people who have had the condition for years or in people who have less controlled 
blood sugar. Excess sugar in the body causes damage to blood vessels in the body and as a result, 
many diabetics suffer from nerve, kidney, eye, and foot damage. Individuals with diabetes have 
also experienced an increased risk of developing cardiovascular disease, Alzheimer’s disease, 
and hypertension.
23 
 As previously mentioned above, OSA causes two mechanisms, intermittent hypoxia and 
sleep fragmentation, which induces several concerns in the body. These concerns range from 
disorders such as sympathetic nervous system activation, oxidative stress, systemic 
inflammation, alterations in hormones, and activation of the hypothalamic-pituitary-adrenal axis. 
This process can lead to the development of insulin resistance which can progress into glucose 
intolerance and eventually diabetes.
24 
 
A study was performed in 2009 that explored the relationship between OSA and insulin 
resistance, glucose intolerance, and T2DM. This cross-sectional study observed 118 non-diabetic 
subjects and conducted a PSG and glucose testing.
30
 Of the 118 subjects, 11 subjects had missing 
sleep pattern information, 39 subjects had no OSA, 34 had mild OSA, 22 subjects had moderate 
OSA, and 23 subjects  had severe OSA. Compared to normal subjects the reduction of insulin 
sensitivity for those with mild, moderate, and severe OSA was 26.7%, 36.5%, and 43.7% 
respectively.
30
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 The effect of CPAP therapy on insulin sensitivity is still unclear. Some studies found that 
subjects on CPAP therapy for at least three months had improved insulin sensitivity and 
metabolic control; while other studies found reduced HbA1c levels and body weight, but were 
unsure if the CPAP treatment or weight loss was the reason for the improved metabolic control.
1
  
2.3 Obstructive Sleep Apnea and Hypertension 
 It is common for individuals to have both OSA and hypertension. Studies have estimated 
that the prevalence of hypertension among OSA patients ranges from 30-70% while an estimated 
30% of hypertensive patients have been undiagnosed. 
25
 In two large population-based studies, 
the odds of prevalent hypertension were twice as high in patients with OSA compared to patients 
without OSA (table 2).  Both studies completed a four-year follow-up and adjusted for known 
confounders such as sex, BMI, and race.
7
  
 The first study was a population-based, cross-sectional study that included 1000 women 
and 741 men. The study was divided into two phases. The first phase consisted of telephone 
interviews conducted on 12,219 women and 4,364 men who were randomly selected from 2 
counties in southern Pennsylvania (Dauphin and Lebanon). They utilized a questionnaire that 
included questions regarding demographics and risk factors for sleep apnea. The second phase 
randomly selected subjects from the telephone interview phase in the sleep laboratory for 
assessment of the presence of sleep apnea. Individuals selected for the second phases were asked 
to provide a comprehensive sleep history, complete physical examination, and psychometric 
assessment of cognitive and psychological functions. The researchers found a dose-response 
pattern among the prevalence of hypertension and three groups; moderate or severe sleep apnea, 
19 
 
mild sleep apnea, and snoring. The odds ratios were 6.8 (2.02-26.36) for moderate or severe 
sleep apnea, 2.3 (1.43-3.61) for mild sleep apnea, and 1.56 (1.09-2.20) for snoring.
5
  
 The second population-based, cross-sectional study was conducted using individuals 
from the Sleep Heart Heath Study. Prior to the baseline home visit, the participants were 
administered a sleep habits questionnaire that included snoring history, sleep apnea awareness, 
sleep apnea treatment, and sleepiness. The home visit included a brief health interview, valuation 
of current medications, blood pressure measurements, and a full unattended PSG. The results 
found that the odds of hypertension among participants with high AHI (≥30 per hour) compared 
to participants with low AHI (≤1.5 per hour) was 2.27 (1.76-2.92).28 
Hypertension (also called high blood pressure) is a condition where the blood vessels 
have consistently raised pressure.
26
 When a heart beats, it creates a force that pushes oxygen-
containing blood through the body. Blood pressure is made up of a combination of force it takes 
for the heart to pump blood out of the heart and the other force is the rest period between heart 
beats. Hypertension is measured using two numbers: systolic and diastolic pressure. Systolic 
pressure is the pressure in the arteries when the heart contracts (heartbeat) while diastolic 
pressure measures the artery pressure when the heart is at rest (between beats). The optimal 
range for blood pressure is a systolic pressure of less than 120 and a diastolic pressure of less 
than 80. You are considered to have hypertension is diagnosed when a systolic pressure of 140-
159 or diastolic pressure is 90-99. This disease is called the “silent killer” because it has no 
symptoms unless an individual goes into hypertensive crisis. Hypertensive crisis is when an 
individual has a systolic pressure of 180 and higher or a diastolic pressure of 110 and higher.
26 
Blood pressure at that level can lead to a stroke in the individual.
26 
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A type of hypertension that is a cause for concern is resistant hypertension. Resistant 
hypertension is when a patient can’t control their blood pressure regardless of the use of a 
diuretic and, at least, two other blood pressure medications. The number of people who suffer 
from resistant hypertension is unknown; however, recent clinical trials estimate the prevalence 
around 10%.
27 
When hypertension goes undiagnosed or uncontrolled, it can cause severe damage to the 
blood vessels and organs. This condition can lead to heart attacks, enlargement of the heart, and 
heart failure. Blood vessels are more likely to clog and burst due to the bulges and weak spots 
the pressure creates. The pressure can also cause blood to leak into the brain, which can increase 
an individual’s risk of a stroke. Hypertension can also increase the risk of blindness, cognitive 
impairment, kidney failure, and rupture of blood vessels.
27 
Blood pressure is affected by OSA because it stops an individual from breathing. 
Anytime breathing is disturbed it causes oxygen levels in the body to drop, and the receptors in 
the brain are alerted. As a result, the brain sends signals to the nervous system, and the blood 
vessels constrict so that oxygen is primarily flowing to the heart and brain. This process can 
carry over into the daytime while OSA patients are awake. The mechanisms that are triggered at 
night by the OSA persist throughout the day and eventually will develop in hypertension.
25 
Chapter 3: Methods  
3.1 Study Design and Study Setting  
This retrospective cohort study examined Kaiser Permanente Georgia (KPGA) adults ≥18 
years of age who were examined at the Sleep Disorder Center of Georgia between the years 
2000-2005 and who were initiated on continuous positive airway pressure (CPAP) therapy 
21 
 
during this period (N=426). Members were followed until December 31, 2010 to determine if 
they had incident T2DM or hypertension by examining diagnoses in computerized medical 
records. 
3.2 Participants 
 Subjects in the study were adults (18≥) Kaiser Permanente members who had been seen 
in at the Sleep Disorder Center of Georgia, tested for OSA, and prescribed CPAP therapy.   
3.3 Variables 
 The primary outcome variables were: the incidence of T2DM, and the incidence of 
hypertension.  Incidence of T2DM was defined as a diagnosis date following the CPAP initiation 
date.  Incidence of hypertension is defined similarly. Diagnosis is determined through evidence 
of disease using relevant diagnosis codes, abnormal test results, or pharmacy dispensings.  
3.4 Data Management 
This study links a CPAP database acquired from the Sleep Disorder Center of Georgia 
with several KPGA databases: membership enrollment, diabetes registry, and hypertension 
registry.  All datasets can be linked by the health record number (HRN).  The CPAP database 
also contains the date of initiation for CPAP and the level of OSA severity classification.  The 
membership enrollment database serves as the source of date of birth, gender, and enrollment 
duration prior to CPAP initiation (number of member months in the 12-months prior to the 
month of CPAP initiation), and a date of disenrollment (if any) following CPAP initiation until 
12/31/2010.  The diabetes and hypertension registries are the source of the dates of initial 
diagnosis (using KPGA registry criteria) of T2DM or hypertension. 
22 
 
3.5 Study Sample  
The CPAP dataset included 719 individuals. The event and comparator numbers of 
patients decreased as additional inclusion and exclusion criteria were imposed (Figure 1). 
Twelve months of observation (KPGA enrollment) prior to the month of the CPAP initiation 
month were required to decrease the likelihood that a patient had T2DM or hypertension prior to 
KPGA enrollment because the member was not enrolled for a sufficient period of time to be 
entered into the diabetes or hypertension registries (which require visits with diagnosis codes, 
abnormal test results, or pharmacy dispensing for entry into the registries).  
3.6 Statistical Methods 
 Individuals were followed through 12/31/2010.  Separate analyses were conducted for 
incident T2DM or incident hypertension.  Within each analysis, the endpoints for Kaplan-Meier 
analysis were defined by: incident T2DM or hypertension prior to 12/31/2010 (event), dis-
enrolled from KPGA prior to 12/31/2010 (censored), or end of study at 12/31/2010 (censored). 
The event time was computed from the CPAP initiation date to the incidence date of 
either T2DM or hypertension.  The censoring dates were computed from the CPAP date to date 
of disenrollment, after seven years of enrollment, or 12/31/2010-whichever occurred first.  Both 
the incident T2DM group and the incident hypertension group were stratified by severity of 
OSA, gender, age group, disease prevalence, and BMI.   A log rank test was conducted for each 
stratified analysis to determine if the risk of incident disease differed by OSA severity, gender, 
age group, comorbid disease, and BMI. A multivariable Cox proportional hazard model was also 
estimated.  
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Chapter 4: Results 
4.1 Study Population 
 A total of 719 patients were diagnosed with OSA during the study period. Of the 719, we 
excluded 103 because they were not enrolled with KPGA for at least a year prior to CPAP 
initiation date. The OSA severity group had two observations missing. In the remaining 614 
patients, 350 (57%) had hypertension before OSA diagnosis date and 125 (20%) had T2DM 
before OSA diagnosis (Figure 1). Therefore, 264 patients were eligible for the analysis of 
incident hypertension and 489 patients were eligible for the analysis of incident T2DM. 
4.2 Descriptive Data  
 Among patients with diagnosed OSA (n=614, 60.1% (n=369) were male, the median age 
was 49 years (IQR 49-56), and 27.0% (n=166) were morbidly obese (Table 3). At time of OSA 
diagnosis, 42.5% (n=261) of patients had severe OSA, 28.5% (n=175) had moderate OSA, and 
29.0% (n=178) had mild OSA.  Compared to patients with mild OSA, those with severe OSA 
were more likely to be morbidly obese (38.7% vs. 19.7%), older (median 50 vs. 48), male 
(67.8% vs. 46.6%), and have both comorbid T2DM (26.1% vs. 18.0%) or comorbid hypertension 
(62.8% vs. 48.9%) at the time of OSA diagnosis (p-value <0.05 for all comparisons).  
4.3 Incident Hypertension  
 Table 2 shows how demographic factors differ between the incident and non-incident 
hypertension group. Of the 265 patients without prevalent hypertension at CPAP initiation, 126 
patients developed hypertension (incident hypertension) and 140 did not develop hypertension 
(non-incident hypertension).  In the incident hypertension group, 33.6% (42 of 125) had mild 
OSA, 28.8% (36 of 125) had moderate OSA, and 37.6% (47 of 125) had severe OSA. Patients in 
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the non-incident hypertension group had 35% (49 of 140) mild OSA, 29.3% (41 of 140) had 
moderate OSA, and 35.7% (50 of 140) had severe OSA (p=0.95). The incident hypertension 
group had more obese 56.5% (70 of 124) compared to the not obese 24.2% (30 of 124) and 
morbidly obese 19.4% (24 of 124) groups (p=0.05). The median age for both incident and non-
incident group was 44. The incident group had more males 60.8% (76 of 125) than females 40% 
(50 of 125; p=0.47). The non-incident hypertension group also had more males 69.3% (97 of 
140) than females 30.7% (43 of 140; p=0.47).  The incident hypertension group had 8% (10 of 
125) of patients that had comorbid T2DM and 92% (115 of 125) did not have comorbid T2DM. 
In the non-incident hypertension group 3.6% (5 of 140) had comorbid T2DM and 96.4% (135 of 
140) did not have T2DM ( p=0.12).  
 A Kaplan-Meier survival curve was calculated using time to hypertension diagnosis and 
severity of OSA (Graph 1). According to the survival curve, patients that suffered from severe 
OSA developed hypertension more quickly following CPAP initiation compared to patients with 
moderate and mild OSA. The p-value for the log rank test was 0.1. A crude and adjusted Cox 
proportional hazard model was estimated for incident hypertension (Table 3). Mild OSA was 
used as the referent group in both calculations. Patients who had moderate OSA had a 2% lower 
risk of developing hypertension in the future (hazard ratio [HR]: 0.98, CI: 0.63-1.53). Also, 
patients with severe OSA had a 48% (HR: 1.48, CI: 0.98-2.25) increased risk of developing 
hypertension in the future compared to patients with mild OSA. Once the hazard ratios were 
adjusted using BMI and comorbid T2DM, the risk of incident hypertension increased slightly for 
moderate OSA by 4% (adjusted [aHR]: 1.04 CI: 0.66-1.64) and decreased by 13% for severe 
OSA (aHR: 1.35 CI: 0.88-2.06).  
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4.4 Incident T2DM 
 In the T2DM sample (n=491), 80 developed diabetes (incident T2DM) and 409 did not 
develop diabetes (non-incident T2DM). Of the 80 patients who developed T2DM, 21.3% (17of 
80) had mild OSA, 26.2% (21 of 80) had moderate OSA, and 51.3% (41 of 80) had severe OSA 
while patients who did not develop T2DM had 31.5% (129 of 409) who had mild OSA, 
31.5%(129 of 409) had moderate OSA, and 37.2% (152 of 409) had severe OSA (p=0.04). The 
incident diabetes group had 13.8% (11 of 80) of patients who were not obese, 47.5% (38 of 80) 
who were obese, and 38.8% (31 of 80) morbidly obese. While patients in the non-incident T2DM 
group had 27.5% (111 of 403) who were not obese, 50.4% (203 of 403) who were obese, 22% 
(89 of 403) who were morbidly obese (p<0.01). The median age was 50 and 47 for the incident 
and non-incident T2DM groups respectively (p=0.13). Both groups had more men than women. 
In the incident T2DM group 68.8% (55 of 80) had comorbid hypertension while 31.2% (25 of 
80) did not have comorbid hypertension. The non-incident group had 45% (185 of 411) with 
comorbid hypertension and 55% (226 of 411) did not have comorbid hypertension (p=<0.01). 
(Table 2) 
 The Kaplan-Meier survival curve was calculated with time to T2DM (in days) based on 
OSA severity. (Graph 2)  The graph shows that patients with severe OSA developed T2DM more 
quickly fallowing CPAP initiation than patients with mild or moderate OSA. The p-value for the 
log rank test was 0.03. A crude and adjusted Cox proportional hazard model was estimated for 
incident T2DM (Table 3). Mild OSA was used as the referent group in both calculations. Patients 
with moderate OSA and severe OSA were at a 23% (HR: 1.23 CI: 0.65-2.33) and 98% (HR: 1.98 
CI:1.12-3.49) increased risk of developing T2DM in the future. After adjusting for BMI and 
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comorbid hypertension, the hazard ratio decreased by 12% (aHR: 1.12 CI: 0.59-2.13) for patients 
with moderate OSA and 49% (aHR: 1.49 CI: 0.83-2.67) for patients with severe OSA.  
Chapter 5: Discussion  
 This study provides some evidence that there is an association between incident T2DM 
and OSA severity. The Cox Proportional hazard models did not show a statistically significant 
association, however the Kaplan-Meier curve did suggest a statistically significant association 
between risk of incident T2DMand severe OSA at the conventional level of p≤ 0.05.  The 
findings from this study did not indicate an association between incident hypertension and OSA 
severity.  The hazard models and Kaplan-Meier curve did not indicate a statistically significant 
association between incident hypertension and OSA severity at the conventional level.  
 One primary reason OSA affects T2DM more than hypertension could be the effect it has 
on the hypothalamic-pituitary-adrenal (HPA) axis. Studies have found that poor sleep quality and 
sleep disorders like OSA can increase the level of individual stress.
31
 This exposure to stress can 
increase the release of glucocorticoids by the HPA, and prolonged activation of the HPA can 
cause harmful changes. These changes can affect puberty, stature, body composition which 
includes obesity, metabolic syndrome, and T2DM.
31 
 There are several limitations to this study. One limitation is the lack of information on 
CPAP adherence of the patients.  Studies that look at the effects of CPAP therapy on conditions 
such as hypertension and T2DM among OSA patients have conflicting findings. Some studies 
have found a decrease in blood pressure and glucose intolerance when CPAP is regularly 
used
6,32
, but other studies do not get similar results
33,34
. This is important because CPAP therapy 
is found to be cumbersome and uncomfortable so more OSA sufferers decide not to use the 
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machine. The results could be skewed the results towards the null hypothesis because patients 
with more severe OSA may adhere to CPAP therapy more than other which could reduce their 
chances of developing hypertension or T2DM. Another limitation is the process by which we 
created the study sample. The patients in this study had to be referred to the sleep clinic by their 
general physician, complete an overnight polysomnography test, and then placed on CPAP 
therapy. These patients had to be relatively compliant to take CPAP therapy, so these patients 
were more likely to be adherent to not only their CPAP therapy but also any other 
recommendations the doctor advises. We have no information on the patients that were referred 
for a sleep study and never completed it. This limitation could skew the results towards the null 
as well since these patients may try to take better care of themselves and decrease their risk of 
other diseases. 
 OSA is a disorder that goes largely undiagnosed and untreated in many people. This 
comes from a lack of knowledge about the disorder and the increased risk it puts people in. Even 
though the findings in this study did not find an association between hypertension and OSA 
severity and a plausible association between T2DM and OSA severity, there were still a large 
number of patients that developed both hypertension (47%) and T2DM (16%). This shows that 
there is some association between them even if it is based on severity. More research needs to be 
done to understand better the relationship between the diseases.  There also needs to be more 
research in if and how CPAP therapy can decrease the risk of developing hypertension and 
T2DM 
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Figures, Tables, and Graphs 
 
 
 
Table 1. Studies of Incidence of Obstructive Sleep Apnea in the general population  
Study Name Number of 
Participants 
Years between 
Follow-Up 
Incidence Reference 
Wisconsin Sleep 
Cohort Study, 
2000 
286 5 16%-Mild OSA 
7.5 Moderate to 
Severe OSA 
Peppard et al., 
2000 
Cleveland 
Family Study, 
2003 
2,968 5 11.1%- Males 
4.9%- Females 
Tishler et al., 
2003 
Sleep Heart 
Health, 2005 
690 4 10.6%- Mild to 
Severe 
Newman et al., 
2005 
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Table 2. Studies on Obstructive Sleep Apnea and Incident Hypertension 
Study Number of 
Participants 
Odds Ratios (CI) 
Bixler et al, 2000 1741 
1000-Females 
741-Males 
6.8 (2.02-26.36)- Moderate to Severe OSA 
2.3 (1.43-3.61)- Mild OSA 
1.56 (1.09-2.20)- Snoring 
Nieto et al, 2000 6,132 
52.8%-Females 
47.2%-Males 
2.27 (1.76-2.92) 
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Figure 1. Flow chart of study sample selection 
 
 
 
 
 
 
  
 
 
 
  
 
 
 
 
 
 
  
 
 
 
  
 
Starting Sample 
of Patients 
616 
103 subjects were removed 
because they not enrolled in a 
Kaiser Permanente healthcare 
plan for at least a year. 
350 subjects were 
removed because of 
hypertension 
diagnosis prior to 
OSA diagnosis. 
125 subjects were 
removed because of 
diabetes diagnosis 
prior to OSA 
diagnosis 
266 491 
126 
Developed 
hypertension 
140  
Did not 
develop 
hypertension 
80 
Developed 
diabetes 
411 
 Did not 
develop 
diabetes 
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*OSA level is categorized as the following: Mild: 5-14AHI, Moderate: 15-29AHI, and Severe:≥30. BMI 
Group: Not Obese: 18.5-29.9, Obese: 30-39.9, Morbidly Obese: ≥40. OSA severity had two individuals 
missing and BMI had six missing individuals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Baseline patient characteristics and obstructive sleep apnea severity classification  
Sample Size 
N=614 
 Mild 
(n=178) 
Moderate 
(n=175) 
Severe 
(n=261) 
p-value 
BMI Group Not Obese 52(30.06%) 41(23.84%) 42(16.34%) <0.01 
Obese 86(49.71%) 101(58.72%) 114(44.36%) 
Morbidly 
Obese 
35(20.23%) 30(17.44%) 101(39.30%) 
Age  Median: 48 
IQR: 48-56 
Median:  48 
IQR: 48-54 
Median: 50 
IOR: 50-56 
0.03 
Gender Female 95(53.37%) 66(37.71%) 84(32.18%) <0.01 
Male 83(46.63%) 109(62.29%) 177(67.82%) 
Prevalent 
Diabetes 
Yes 32(17.98%) 25(14.29%) 68(26.05%) <0.01 
No 146(82.02%) 150(85.71%) 193(73.95%) 
Prevalent 
Hypertension 
Yes 87(48.88%) 98(56.00%) 164(62.84%) 0.01 
No 91(51.12%) 77(44.00%) 97(37.16%) 
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Table 4. Descriptive information of study sample by incident Hypertension and Type 2 Diabetes 
 Incident Hypertension (HTN) Sample 
(N=265) 
Incident Type 2 Diabetes (DM) 
Sample (N=489) 
With 
Incident  
HTN 
Without 
Incident 
HTN 
P-
value 
With 
Incident 
DM 
Without 
Incident DM 
P-
value 
N of Patients 125 
(47.17%) 
140 -- 80 (16.36%) 409 -- 
OSA Level Mild 
 
42(34.75%) 49(34.02%) 0.95 17(21.52%) 129(31.46%) 0.04 
Moderate 
 
36(27.12%) 41(30.61%) 21(26.58%) 129(31.47%) 
Severe 
 
47(38.14%) 50(35.37%) 41(51.90%) 152(37.07%) 
BMI Group Not Obese 
 
30(22.41%) 51(37.76%) 0.05 11(13.92%) 111(27.36%) <0.0
1 
Obese 
 
70(56.90%) 59(44.06%) 38(48.10%) 203(50.50%) 
Morbidly 
Obese 
 
24(20.69%) 26(18.18%) 31(37.98%) 89(22.14%) 
Age  Median:44 
IQR: 17 
Median:44 
IQR:14 
0.47 Median:50 
IQR:12 
Median:47 
IQR:15 
0.13 
Gender Female 
 
50(41.38%) 43(29.37%) 0.13 36(45.57%) 151(36.59%) 0.16 
Male 
 
75(58.62%) 97(70.63%) 44(54.43%) 260(63.41%) 
Comorbid 
Disease 
Yes 
 
10 (8.62%) 5(3.50%) 0.12 55(68.35%) 185(45.12%) <0.0
1 
No 
 
115 
(91.38%) 
135(96.50%) 25(31.65%) 226(54.88%) 
* OSA level is categorized as the following: Mild: 5-14AHI, Moderate: 15-29AHI, and Severe:≥30. BMI 
Group: Not Obese: 18.5-29.9, Obese: 30-39.9, Morbidly Obese: ≥40. Comorbid disease for incident 
hypertension sample is T2DM. Comorbid disease for T2DM sample is hypertension. OSA severity had 
two individuals missing and BMI had six missing individuals.  
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* Adjusted ratios were calculated using BMI and prevalent comorbidity. OSA severity had two 
individuals missing. OSA level is categorized as the following: Mild: 5-14AHI, Moderate: 15-29AHI, and 
Severe: ≥30. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Crude and Adjusted Hazard Ratios for Incident Type 2 Diabetes and Hypertension by 
Obstructive Sleep Apnea Severity 
 Incident DM Incident HTN 
Median 
Time  
(Years) to 
Incident DM 
Crude 
Hazard Ratio 
Adjusted 
Hazard Ratio 
Median Time 
(Years)to 
Incident HTN 
Crude 
Hazard Ratio 
Adjusted 
Hazard Ratio 
Mild OSA Median:3.01 
IQR:2.79 
1.00 1.00 Median:2.46  
IQR: 2.59 
1.00 1.00 
Moderate 
OSA 
Median:2.17 
IQR: 1.25 
1.23(CI:0.65-
2.33) 
1.12(CI:0.59-
2.13) 
Median: 
3.17 
IQR: 2.20 
0.98(CI: 
0.63-1.53) 
1.04(CI:0.66-
1.64) 
Severe 
OSA 
Median:2.57 
IQR: 3.42 
1.98(1.12-
3.49) 
1.49(CI:0.83-
2.67) 
Median: 
2.38 
IQR: 2.05 
1.48(CI:0.98-
2.25) 
1.35(CI:0.88-
2.06 
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Log-Rank Test= 0.1 
Graph 1. Kaplan-Meier Survival Curve for Incident 
Hypertension and Obstructive Sleep Apnea Severity 
Proportion 
without 
Hypertension 
25 
39 
 
 
 
 
 
Log-Rank Test=0.03 
Graph 2. Kaplan-Meier Survival Curve for Incident Type 2 
Diabetes and Obstructive Sleep Apnea Severity 
Proportion 
without 
Diabetes 
24 
